Natalie Tapaskar, MD

DocwireNews

There are limited medical options for patients with advanced heart failure who are not candidates for heart transplantation or durable left ventricular assist device (LVAD). The use of palliative inotrope therapy for this population has been controversial with unclear efficacy and benefit.1,2 Dr. Farhad Sami and co-investigators sought to understand the impact of palliative home dobutamine versus home milrinone on 1-year survival in a contemporary cohort of patients with advanced heart failure admitted with cardiogenic shock, who were not candidates for heart transplant or LVAD.1
The study included 133 patients discharged with IV milrinone and 115 patients discharged with IV dobutamine. Baseline invasive hemodynamics and background beta-blocker and RAAS inhibitor therapy were similar between the two groups. However, at the time of discharge, more patients in the IV milrinone group were on beta-blockers (42.4 vs 8.8%) and mineralocorticoid antagonist therapy (72 vs 60%).1
Patients discharged with IV dobutamine had higher mortality at 1-year follow up when compared with those discharged with IV milrinone (84% vs 58%, p &lt;0.001). Median survival in the IV milrinone group was 8.9 months compared with 4.4 months in the IV dobutamine group. However, in a multivariate analysis adjusting for discharge medications and comorbidities, the type of IV inotrope did not significantly predict 6-month survival.1
This study suggests that the higher mortality risk with home IV dobutamine compared to IV milrinone may be due to decreased concomitant GDMT use, rather than the mechanism of the inotropes themselves. This would align with our contemporary knowledge that GDMT improves mortality in patients with heart failure.3,4
This work builds upon a larger body of literature investigating the optimal inotrope for management of acute cardiogenic shock. The CAPITAL DOREMI trial was a single center randomized controlled trial of dobutamine versus milrinone for cardiogenic shock.5 The study surprisingly found no difference in the composite primary outcome of in-hospital death, resuscitated cardiac arrest, receipt of cardiac transplant or mechanical support, nonfatal myocardial infarction, stroke, or initiation of renal replacement therapy.5
CAPITAL DOREMI 2 is a follow-up study that is currently enrolling patients and will be a multicenter placebo-controlled trial of dobutamine versus milrinone in the initial resuscitation of cardiogenic shock. The expected study completion date is 2026.
While we eagerly await the results of DOREMI 2, it seems the jury is still out on the best inotrope strategy for both the acute management of cardiogenic shock and palliative therapy for patients with advanced heart failure.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Milrinone at home with beta-blockers and GDMT may be better than dobutamine. 
Hypothesis generating data.
Palliative Inotropes in Advanced Heart Failure: Comparing Outcomes Between Milrinone and Dobutamine &#8211; Journal of Cardiac Failure <a href="https://t.co/HYAOrwBPv1">https://t.co/HYAOrwBPv1</a>
&mdash; Andrew J Sauer MD (@AndrewJSauer) <a href="https://twitter.com/AndrewJSauer/status/1571138460181741570?ref_src=twsrc%5Etfw">September 17, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
References. 
<ol>
<li>Sami F, Acharya P, Noonan G, et al. Palliative Inotropes in Advanced Heart Failure: Comparing Outcomes Between Milrinone and Dobutamine. Journal of Cardiac Failure. Published online September 2022:S1071916422007114. doi:10.1016/j.cardfail.2022.08.007</li>
<li>Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation. 2003;108(4):492-497. doi:10.1161/01.CIR.0000078349.43742.8A</li>
<li>Tran RH, Aldemerdash A, Chang P, et al. Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure. Pharmacotherapy. 2018;38(4):406-416. doi:10.1002/phar.2091</li>
<li>Gilstrap LG, Fonarow GC, Desai AS, et al. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc. 2017;6(2):e004675. doi:10.1161/JAHA.116.004675</li>
<li>Mathew R, Di Santo P, Jung RG, et al. Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. N Engl J Med. 2021;385(6):516-525. doi:10.1056/NEJMoa2026845</li>
</ol>

Dr. MarkAlain Déry

Rob Dillard

Dr. MarkAlain Déry: Hurricane Associated Power Failures Can Devastate Health Care Facilities

Hurricanes & Health Care

Dr. MarkAlain Déry Explains How Hurricane Katrina Changed Health Care Protocols

Dr. MarkAlain Déry on How Hurricanes Impact the Health Care System

Latest News

Milrinone vs Dobutamine for Heart Failure: Where Do We Stand?

Cardionerds is an entertaining and educational medical cardiology podcast created by three cardiologists. They want to bring high yield cardiovascular concepts in a fun and engaging format for their listeners of all levels. Click below to learn more!

CardioNerds

There are limited medical options for patients with advanced heart failure who are not candidates for heart transplantation or durable left ventricular assist device (LVAD). ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe